NCT01564563终止2 期
A Multi-center, Randomized, Double-blind, Parallel Groups, Placebo-controlled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation (HSCT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Effect on bleeding, defined as change in bleeding score
研究概览
简要总结
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have undergone a hematopoietic stem cell transplantation
排除标准
- •Known or suspected allergy to trial product
- •Participation in other trials with unapproved drugs or trials with equal or similar objective
研究组 & 干预措施
Low dose
Experimental
干预措施: standard therapy (Drug)
Low dose
Experimental
干预措施: activated recombinant human factor VII (Drug)
High dose
Experimental
干预措施: standard therapy (Drug)
High dose
Experimental
干预措施: activated recombinant human factor VII (Drug)
Placebo
Placebo Comparator
干预措施: standard therapy (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Effect on bleeding, defined as change in bleeding score
次要结局
- Changes in safety coagulation parameters
- Transfusion requirements
- Bleeding evaluation
- Adverse events
研究者
研究点 (1)
Loading locations...
相似试验
撤回
3 期
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to TraumaAcquired Bleeding DisorderTraumaNCT00323570Novo Nordisk A/S
已完成
2 期
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageAcquired Bleeding DisorderIntracerebral HaemorrhageNCT01563445Novo Nordisk A/S40
已完成
2 期
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With MetforminDiabetes Mellitus Type 2DiabetesNCT02205528Novo Nordisk A/S108
已完成
1 期
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01464099Novo Nordisk A/S24
已完成
1 期
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01497600Novo Nordisk A/S50